134 related articles for article (PubMed ID: 36753617)
21. Characterization of elongin C functional domains required for interaction with elongin B and activation of elongin A.
Takagi Y; Conaway RC; Conaway JW
J Biol Chem; 1996 Oct; 271(41):25562-8. PubMed ID: 8810329
[TBL] [Abstract][Full Text] [Related]
22. Genetic and pharmacological strategies to refunctionalize the von Hippel Lindau R167Q mutant protein.
Ding Z; German P; Bai S; Reddy AS; Liu XD; Sun M; Zhou L; Chen X; Zhao X; Wu C; Zhang S; Mills GB; Jonasch E
Cancer Res; 2014 Jun; 74(11):3127-36. PubMed ID: 24755468
[TBL] [Abstract][Full Text] [Related]
23. VHL-box and SOCS-box domains determine binding specificity for Cul2-Rbx1 and Cul5-Rbx2 modules of ubiquitin ligases.
Kamura T; Maenaka K; Kotoshiba S; Matsumoto M; Kohda D; Conaway RC; Conaway JW; Nakayama KI
Genes Dev; 2004 Dec; 18(24):3055-65. PubMed ID: 15601820
[TBL] [Abstract][Full Text] [Related]
24. Calcineurin promotes hypoxia-inducible factor 1alpha expression by dephosphorylating RACK1 and blocking RACK1 dimerization.
Liu YV; Hubbi ME; Pan F; McDonald KR; Mansharamani M; Cole RN; Liu JO; Semenza GL
J Biol Chem; 2007 Dec; 282(51):37064-73. PubMed ID: 17965024
[TBL] [Abstract][Full Text] [Related]
25. Direct regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and MET.
Rankin EB; Fuh KC; Castellini L; Viswanathan K; Finger EC; Diep AN; LaGory EL; Kariolis MS; Chan A; Lindgren D; Axelson H; Miao YR; Krieg AJ; Giaccia AJ
Proc Natl Acad Sci U S A; 2014 Sep; 111(37):13373-8. PubMed ID: 25187556
[TBL] [Abstract][Full Text] [Related]
26. Spermidine/spermine-N1-acetyltransferase 2 is an essential component of the ubiquitin ligase complex that regulates hypoxia-inducible factor 1alpha.
Baek JH; Liu YV; McDonald KR; Wesley JB; Hubbi ME; Byun H; Semenza GL
J Biol Chem; 2007 Aug; 282(32):23572-80. PubMed ID: 17558023
[TBL] [Abstract][Full Text] [Related]
27. Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C.
Kibel A; Iliopoulos O; DeCaprio JA; Kaelin WG
Science; 1995 Sep; 269(5229):1444-6. PubMed ID: 7660130
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of transcription elongation by the VHL tumor suppressor protein.
Duan DR; Pause A; Burgess WH; Aso T; Chen DY; Garrett KP; Conaway RC; Conaway JW; Linehan WM; Klausner RD
Science; 1995 Sep; 269(5229):1402-6. PubMed ID: 7660122
[TBL] [Abstract][Full Text] [Related]
29. Hepatocyte growth factor-stimulated renal tubular mitogenesis: effects on expression of c-myc, c-fos, c-met, VEGF and the VHL tumour-suppressor and related genes.
Clifford SC; Czapla K; Richards FM; O'Donoghue DJ; Maher ER
Br J Cancer; 1998 May; 77(9):1420-8. PubMed ID: 9652757
[TBL] [Abstract][Full Text] [Related]
30. The Elongin BC complex and the von Hippel-Lindau tumor suppressor protein.
Conaway JW; Kamura T; Conaway RC
Biochim Biophys Acta; 1998 Apr; 1377(2):M49-54. PubMed ID: 9606976
[No Abstract] [Full Text] [Related]
31. The Hsp70 and TRiC/CCT chaperone systems cooperate in vivo to assemble the von Hippel-Lindau tumor suppressor complex.
Melville MW; McClellan AJ; Meyer AS; Darveau A; Frydman J
Mol Cell Biol; 2003 May; 23(9):3141-51. PubMed ID: 12697815
[TBL] [Abstract][Full Text] [Related]
32. A molecular basis for stabilization of the von Hippel-Lindau (VHL) tumor suppressor protein by components of the VHL ubiquitin ligase.
Kamura T; Brower CS; Conaway RC; Conaway JW
J Biol Chem; 2002 Aug; 277(33):30388-93. PubMed ID: 12048197
[TBL] [Abstract][Full Text] [Related]
33. Identification of a novel protein (VBP-1) binding to the von Hippel-Lindau (VHL) tumor suppressor gene product.
Tsuchiya H; Iseda T; Hino O
Cancer Res; 1996 Jul; 56(13):2881-5. PubMed ID: 8674032
[TBL] [Abstract][Full Text] [Related]
34. Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma.
Müller J; Krijgsman O; Tsoi J; Robert L; Hugo W; Song C; Kong X; Possik PA; Cornelissen-Steijger PD; Geukes Foppen MH; Kemper K; Goding CR; McDermott U; Blank C; Haanen J; Graeber TG; Ribas A; Lo RS; Peeper DS
Nat Commun; 2014 Dec; 5():5712. PubMed ID: 25502142
[TBL] [Abstract][Full Text] [Related]
35. Peptide-mediated inhibition of the transcriptional regulator Elongin BC induces apoptosis in cancer cells.
Fischer S; Trinh VT; Simon C; Weber LM; Forné I; Nist A; Bange G; Abendroth F; Stiewe T; Steinchen W; Liefke R; Vázquez O
Cell Chem Biol; 2023 Jul; 30(7):766-779.e11. PubMed ID: 37354906
[TBL] [Abstract][Full Text] [Related]
36. Insights into Cullin-RING E3 ubiquitin ligase recruitment: structure of the VHL-EloBC-Cul2 complex.
Nguyen HC; Yang H; Fribourgh JL; Wolfe LS; Xiong Y
Structure; 2015 Mar; 23(3):441-449. PubMed ID: 25661653
[TBL] [Abstract][Full Text] [Related]
37. The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins.
Pause A; Lee S; Worrell RA; Chen DY; Burgess WH; Linehan WM; Klausner RD
Proc Natl Acad Sci U S A; 1997 Mar; 94(6):2156-61. PubMed ID: 9122164
[TBL] [Abstract][Full Text] [Related]
38. RACK1 competes with HSP90 for binding to HIF-1alpha and is required for O(2)-independent and HSP90 inhibitor-induced degradation of HIF-1alpha.
Liu YV; Baek JH; Zhang H; Diez R; Cole RN; Semenza GL
Mol Cell; 2007 Jan; 25(2):207-17. PubMed ID: 17244529
[TBL] [Abstract][Full Text] [Related]
39. Solution structure and dynamics of yeast elongin C in complex with a von Hippel-Lindau peptide.
Botuyan MV; Mer G; Yi GS; Koth CM; Case DA; Edwards AM; Chazin WJ; Arrowsmith CH
J Mol Biol; 2001 Sep; 312(1):177-86. PubMed ID: 11545595
[TBL] [Abstract][Full Text] [Related]
40. AXL/AKT axis mediated-resistance to BRAF inhibitor depends on PTEN status in melanoma.
Zuo Q; Liu J; Huang L; Qin Y; Hawley T; Seo C; Merlino G; Yu Y
Oncogene; 2018 Jun; 37(24):3275-3289. PubMed ID: 29551771
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
